We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
+12.44%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.31B
AUM Growth
+$49.5M
Cap. Flow
-$34.5M
Cap. Flow %
-2.63%
Top 10 Hldgs %
65.03%
Holding
329
New
20
Increased
146
Reduced
123
Closed
37

Top Sells

Rank Stock Value
1
GRAB icon
Grab
GRAB
+$40.9M
2
NVDA icon
NVIDIA
NVDA
+$7.7M
3
MSFT icon
Microsoft
MSFT
+$6.02M
4
STAA icon
STAAR Surgical
STAA
+$5.62M
5
SE icon
Sea Limited
SE
+$3.76M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 45.37%
2 Technology 25.37%
3 Communication Services 8.93%
4 Healthcare 6.43%
5 Real Estate 6.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADMA icon
276
ADMA Biologics
ADMA
$1.92B
$115K 0.01%
32,129
-6,484
-17% -$25K
ARQT icon
277
Arcutis Biotherapeutics
ARQT
$3.42B
$114K 0.01%
21,535
-5,342
-20% -$45.4K
MCRB icon
278
Seres Therapeutics
MCRB
$48.1M
$114K 0.01%
2,405
+326
+16% +$24.9K
CDNA icon
279
CareDx
CDNA
$1.92B
$110K 0.01%
15,683
-2,754
-15% -$25.4K
KURA icon
280
Kura Oncology
KURA
$922M
$109K 0.01%
11,929
+1,301
+12% +$13.2K
RNAM
281
DELISTED
Avidity Biosciences
RNAM
$108K 0.01%
16,965
-12,499
-42% -$108K
VTRS icon
282
Viatris
VTRS
$20.1B
$105K 0.01%
10,641
-1,375
-11% -$14.3K
AGEN
283
Agenus
AGEN
$249M
$98K 0.01%
4,317
+451
+12% +$12.8K
ALDX icon
284
Aldeyra Therapeutics
ALDX
$91.7M
$93K 0.01%
13,939
+327
+2% +$2.43K
AVXL icon
285
Anavex Life Sciences
AVXL
$222M
$91K 0.01%
13,908
-4,945
-26% -$39.4K
MDXG icon
286
MiMedx Group
MDXG
$626M
$84K 0.01%
+11,535
New +$85.9K
PNT
287
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$76K 0.01%
11,463
+939
+9% +$7.8K
SANA icon
288
Sana Biotechnology
SANA
$885M
$65K ﹤0.01%
16,688
-1,366
-8% -$7.34K
EQRX
289
DELISTED
EQRx, Inc. Common Stock
EQRX
$60K ﹤0.01%
26,843
-6,479
-19% -$13.9K
SCLX icon
290
Scilex Holding
SCLX
$48.1M
$44K ﹤0.01%
898
LYEL icon
291
Lyell Immunopharma
LYEL
$309M
$32K ﹤0.01%
1,091
+216
+25% +$10.3K
AGIO icon
292
Agios Pharmaceuticals
AGIO
$2.16B
-8,793
Closed -$249K
ALLK
293
DELISTED
Allakos
ALLK
-18,996
Closed -$83K
ARCT icon
294
Arcturus Therapeutics
ARCT
$157M
-8,523
Closed -$244K
BA icon
295
Boeing
BA
$165B
-945
Closed -$200K
BTAI icon
296
BioXcel Therapeutics
BTAI
$26.2M
-664
Closed -$71K
CCL icon
297
Carnival Corporation Ltd
CCL
$36.1B
-71,320
Closed -$1.34M
COGT icon
298
Cogent Biosciences
COGT
$6.79B
-11,088
Closed -$131K
EBS icon
299
Emergent Biosolutions
EBS
$375M
-31,274
Closed -$230K
EW icon
300
Edwards Lifesciences
EW
$47.6B
-2,126
Closed -$201K

Similar funds

E Fund Management's Q3 2023 Portfolio in Review

As of Q3 2023, E Fund Management held 329 positions worth $1.31B, up 3.9% from $1.26B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

E Fund Management's Q3 2023 filing shows 20 new, 146 increased, 123 reduced and 37 closed positions. Its largest new stake was iShares MSCI Global Gold Miners ETF: 148,564 shares worth $3.08M. The largest sale was Grab, an estimated $40.9M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 37% a quarter earlier, followed by Technology and Communication Services.

  • E Fund Management's largest Q3 2023 buy was iShares MSCI Global Gold Miners ETF: 148,564 shares worth $3.08M.
  • E Fund Management added most to KLA in Q3 2023, an estimated $10.2M increase.
  • E Fund Management's biggest Q3 2023 reduction was NVIDIA, cutting an estimated $7.7M.
  • E Fund Management fully exited Grab in Q3 2023, selling an estimated $40.9M.
  • E Fund Management's ten largest holdings make up 65% of its $1.31B portfolio in Q3 2023.
  • E Fund Management opened 20 new positions and closed 37 in Q3 2023.
  • E Fund Management's portfolio value rose 3.9% quarter-over-quarter to $1.31B.

Based on E Fund Management's 13F filing for Q3 2023, filed 13 Nov 2023.